Which new penetrating keratoplasty and glaucoma (PKPG) treatments are under investigation?

Updated: Dec 30, 2020
  • Author: Shibandri Das, MD; Chief Editor: Inci Irak Dersu, MD, MPH  more...
  • Print

Research on new and alternative therapies is ongoing. In the case of medical treatments, whereas latanoprostene bunod and netarsudil are used for glaucoma, data are needed as to their efficacy and adverse effects in PKPG. Regarding surgical treatments, 2 small studies (n = 10) on the use of trabeculotomy for PKPG showed effective lowering of IOP, with no graft rejection at 72-month follow-up and no acceleration of corneal endothelial cell loss. [87, 88]  The results of these studies suggest that better management of PKPG may prolong the life of the graft.

Borderie and colleagues [19, 89]  conducted studies in which they found that deep anterior lamellar keratoplasty and endothelial keratoplasties had a better long-term outcome in terms of graft survival and endothelial densities than penetrating keratoplasty. [90]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!